Story · Medicine & Biotech
Pelacarsen Fails to Reduce Cardiovascular Events Despite Lowering Lp(a): NEJM
1 outlet · first reported by Medical Dialogues on
USA: The Lp(a) HORIZON trial found that pelacarsen did not reduce major cardiovascular events in patients with elevated lipoprotein(a) and pre-existing cardiovascular disease. Over nearly five years, pelacarsen failed to significantly reduce the composite primary endpoint of cardiovascular death… (Medical Dialogues)
Coverage, in order
-
Pelacarsen Fails to Reduce Cardiovascular Events Despite Lowering Lp(a): NEJMUSA: The Lp(a) HORIZON trial found that pelacarsen did not reduce major cardiovascular events in patients with elevated lipoprotein(a) and pre-existing cardiovascular disease. Over nearly five years, pelacarsen failed to significantly reduce the composite primary endpoint of cardiovascular death…
Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.